Manfred Frick

Prof. Manfred Frick

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JMJanis Müller
Janis Müller
RGRüdiger Groß
Rüdiger Groß
CCCarina Conzelmann
Carina Conzelmann
JKJana Krüger
Jana Krüger
UMUta Merle
Uta Merle
AKAlexander Kleger
Alexander Kleger

25 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJanick D. Stucki
Janick D. Stucki
NHNina Hobi
Nina Hobi
AGArtur Galimov
Artur Galimov
ASAndreas O. Stucki
Andreas O. Stucki
NSNicole Schneider-Daum
Nicole Schneider-Daum
OGOlivier Guenat
Olivier Guenat
Organs-on-chips have the potential to improve drug development efficiency and decrease the need for animal testing. For the successful integration of these devices in research and industry, they must reproducein vivocontexts as closely as possible and be easy to use. Here, we describe a ‘breathing’ lung-on-chip array equipped with a passive medium exchange mechanism that provide anin vivo-like environment to primary human lung alveolar cells (hAEpCs) and primary lung endothelial cells. This configuration allows the preservation of the phenotype and the function of hAEpCs for several days, the conservation of the epithelial barrier functionality, while enabling simple sampling of the supernatant from the basal chamber. In addition, the chip design increases experimental throughput and enables trans-epithelial electrical resistance measurements using standard equipment. Biological validation revealed that human primary alveolar type I (ATI) and type II-like (ATII) epithelial cells could be successfully cultured on the chip over multiple days. Moreover, the effect of the physiological cyclic strain showed that the epithelial barrier permeability was significantly affected. Long-term co-culture of primary human lung epithelial and endothelial cells demonstrated the potential of the lung-on-chip array for reproducible cell culture under physiological conditions. Thus, this breathing lung-on-chip array, in combination with patients’ primary ATI, ATII, and lung endothelial cells, has the potential to become a valuable tool for lung research, drug discovery and precision medicine.

19 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLukas Wettstein
Lukas Wettstein
TWTatjana Weil
Tatjana Weil
CCCarina Conzelmann
Carina Conzelmann
JMJanis Müller
Janis Müller
RGRüdiger Groß
Rüdiger Groß
JMJan Münch
Jan Münch
SARS-CoV-2 is a respiratory pathogen and primarily infects the airway epithelium. As our knowledge about innate immune factors of the respiratory tract against SARS-CoV-2 is limited, we generated and screened a peptide/protein library derived from bronchoalveolar lavage for inhibitors of SARS-CoV-2 spike-driven entry. Analysis of antiviral fractions revealed the presence of α1-antitrypsin (α1AT), a highly abundant circulating serine protease inhibitor. Here, we report that α1AT inhibits SARS-CoV-2 entry at physiological concentrations and suppresses viral replication in cell lines and primary cells including human airway epithelial cultures. We further demonstrate that α1AT binds and inactivates the serine protease TMPRSS2, which enzymatically primes the SARS-CoV-2 spike protein for membrane fusion. Thus, the acute phase protein α1AT is an inhibitor of TMPRSS2 and SARS-CoV-2 entry, and may play an important role in the innate immune defense against the novel coronavirus. Our findings suggest that repurposing of α1AT-containing drugs has prospects for the therapy of COVID-19.

3 August 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KDKathrin Diem
Kathrin Diem
MFMichael Fauler
Michael Fauler
GFGiorgio Fois
Giorgio Fois
AHAndreas Hellmann
Andreas Hellmann
NWNatalie Winokurow
Natalie Winokurow
MFManfred Frick
Manfred Frick
Secretion of pulmonary surfactant in the alveoli of the lungs is essential to maintain lung function. Stretching of alveoli during lung inflation is the main trigger for surfactant secretion. Yet, the molecular mechanisms how mechanical distension of alveoli results in surfactant secretion are still elusive. The alveolar epithelium consists of alveolar epithelial type I (ATI) and surfactant secreting type II (ATII) cells. ATI, but not ATII cells, express caveolae, small plasma membrane invaginations that can respond to plasma membrane stresses and serve mechanotransductive roles. Within this study, we investigated the role of caveolae as mechanosensors in the alveolus. We generated a human caveolin‐1 knockout ATI cell (hAELVi cav−/− ) using CRISPR/Cas9. Wildtype (hAELVi wt ) and hAELVi cav−/− cells grown on flexible membranes responded to increasing stretch amplitudes with rises in intracellular Ca 2+ . The response was less frequent and started at higher stretch amplitudes in hAELVi cav−/− cells. Stretch‐induced Ca 2+ ‐signals depended on Ca 2+ ‐entry via piezo1 channels, localized within caveolae in hAELVi wt and primary ATI cells. Ca 2+ ‐entry via piezo1 activated pannexin‐1 hemichannels resulting in ATP release from ATI cells. ATP release was reduced in hAELVi cav−/− cells. In co‐cultures resembling the alveolar epithelium, released ATP stimulated Ca 2+ signals and surfactant secretion from neighboring ATII cells when co‐cultured with hAELVi wt but not hAELVi cav−/− cells. In summary, we propose that caveolae in ATI cells are mechanosensors within alveoli regulating stretch‐induced surfactant secretion from ATII cells.

15 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PMPika Miklavc
Pika Miklavc
NMNorbert Mair
Norbert Mair
OWOliver H. Wittekindt
Oliver H. Wittekindt
THThomas Haller
Thomas Haller
PDPaul Dietl
Paul Dietl
MFManfred Frick
Manfred Frick
Ca 2+ is considered a key element in multiple steps during regulated exocytosis. During the postfusion phase, an elevated cytoplasmic Ca 2+ concentration ([Ca 2+ ]) c leads to fusion pore dilation. In neurons and neuroendocrine cells, this results from activation of voltage-gated Ca 2+ channels in the plasma membrane. However, these channels are activated in the prefusion stage, and little is known about Ca 2+ entry mechanisms during the postfusion stage. This may be particularly important for slow and nonexcitable secretory cells. We recently described a “fusion-activated“ Ca 2+ entry (FACE) mechanism in alveolar type II (ATII) epithelial cells. FACE follows initial fusion pore opening with a delay of 200–500 ms. The site, molecular mechanisms, and functions of this mechanism remain unknown, however. Here we show that vesicle-associated Ca 2+ channels mediate FACE. Using RT-PCR, Western blot analysis, and immunofluorescence, we demonstrate that P2X 4 receptors are expressed on exocytotic vesicles known as lamellar bodies (LBs). Electrophysiological, pharmacological, and genetic data confirm that FACE is mediated via these vesicular P2X 4 receptors. Furthermore, analysis of fluorophore diffusion into and out of individual vesicles after exocytotic fusion provides evidence that FACE regulates postfusion events of LB exocytosis via P2X 4 . Fusion pore dilation was clearly correlated with the amplitude of FACE, and content release from fused LBs was accelerated in fusions followed by FACE. Based on these findings, we propose a model for regulation of the exocytotic postfusion phase in nonexcitable cells in which Ca 2+ influx via vesicular Ca 2+ channels regulates fusion pore expansion and vesicle content release.

23 March 2022 in Nature
Verified
Journal Article
Open access
PDF file
YLYing Lai
Ying Lai
GFGiorgio Fois
Giorgio Fois
JFJose R. Flores
Jose R. Flores
MTMichael J. Tuvim
Michael J. Tuvim
QZQiangjun Zhou
Qiangjun Zhou
ABAxel T. Brunger
Axel T. Brunger
Membrane fusion triggered by Ca2+ is orchestrated by a conserved set of proteins to mediate synaptic neurotransmitter release, mucin secretion and other regulated exocytic processes1–4. For neurotransmitter release, the Ca2+ sensitivity is introduced by interactions between the Ca2+ sensor synaptotagmin and the SNARE complex5, and sequence conservation and functional studies suggest that this mechanism is also conserved for mucin secretion6. Disruption of Ca2+-triggered membrane fusion by a pharmacological agent would have therapeutic value for mucus hypersecretion as it is the major cause of airway obstruction in the pathophysiology of respiratory viral infection, asthma, chronic obstructive pulmonary disease and cystic fibrosis7–11. Here we designed a hydrocarbon-stapled peptide that specifically disrupts Ca2+-triggered membrane fusion by interfering with the so-called primary interface between the neuronal SNARE complex and the Ca2+-binding C2B domain of synaptotagmin-1. In reconstituted systems with these neuronal synaptic proteins or with their airway homologues syntaxin-3, SNAP-23, VAMP8, synaptotagmin-2, along with Munc13-2 and Munc18-2, the stapled peptide strongly suppressed Ca2+-triggered fusion at physiological Ca2+ concentrations. Conjugation of cell-penetrating peptides to the stapled peptide resulted in efficient delivery into cultured human airway epithelial cells and mouse airway epithelium, where it markedly and specifically reduced stimulated mucin secretion in both systems, and substantially attenuated mucus occlusion of mouse airways. Taken together, peptides that disrupt Ca2+-triggered membrane fusion may enable the therapeutic modulation of mucin secretory pathways.